In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anagenesis Biotechnologies

http://www.anagenesis-biotech.com/

Latest From Anagenesis Biotechnologies

Viatris’ Mylan And Apotex Lose Again Over US Bendeka Patents

Viatris’ Mylan and Apotex once again fell to Teva and Eagle Pharmaceuticals in their battle to introduce generic versions of the rapid-infusion bendamustine formulation, Bendeka, with the US Federal Circuit upholding a lower court judgement.

Generic Drugs Intellectual Property

Who’s Hired? Stada Names New Specialty Head

Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.

Executive Changes Strategy

Slayback Exclusivity On Taytulla Does Not Bar Rival ANDA Product

Slayback Pharma has now launched its Merzee generic version of Allergan’s Taytulla oral contraceptive with a CGT designation, several months after Xiromed moved first.

Generic Drugs Launches

Slayback Rivals Xiromed On Taytulla – But With First CGT Designation

US-based player Slayback “will kick off a full commercial launch under its own label very soon” of the generic version of Allergan’s Taytulla for which it has just received approval with a competitive generic therapy designation.

Approvals Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register